Norgine Awaits European Commission's Decision on Mavorixafor for WHIM Syndrome

Norgine B.V. has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for their drug XOLREMDI® (mavorixafor). This marks a significant step toward the first authorized treatment for WHIM syndrome in Europe. The drug, intended for patients aged 12 and older, addresses the chemokine receptor dysfunction that characterizes WHIM syndrome, aiding in the mobilization of white blood cells to improve immune response.

The European Commission is expected to make a final decision on approval in the second quarter of 2026. Norgine has partnered with X4 Pharmaceuticals for the drug's commercialization in Europe, Australia, and New Zealand. This collaboration is pivotal for bringing mavorixafor to the market, should the European Commission's decision be affirmative. The phase 3 clinical trials have already demonstrated the drug's efficacy and safety, giving hope to those suffering from this rare condition.